Aspire Biopharma Holdings, Inc. - Common Stock (ASBP)

0.2450
+0.0450 (22.50%)
NASDAQ · Last Trade: Apr 27th, 5:20 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close0.2000
Open0.2500
Bid0.2300
Ask0.2312
Day's Range0.2108 - 0.3100
52 Week Range0.1643 - 35.01
Volume208,257,076
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume16,370,637

Chart

News & Press Releases

What's going on in today's after hours sessionchartmill.com
Via Chartmill · April 27, 2026
Monday's session: most active stockschartmill.com
Via Chartmill · April 27, 2026
Aspire Biopharma Announces $5.0 Million Share Repurchase Program
ESTERO, FL / ACCESS Newswire / April 27, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that its Board of Directors (the "Board") has authorized the repurchase of up to $5.0 million of the Company's common stock. The authorization reflects the Board's confidence in the Company's balance sheet strength, the value of its drug development pipeline and supplement business, and the potential value creation from the recently announced Binding Letter of Intent (LOI) to acquire Dura Driver Control Systems (DCS).
Via ACCESS Newswire · April 27, 2026
The trading volume of these stocks is deviating from the norm in today's session.chartmill.com
Via Chartmill · April 22, 2026
Top movers in Tuesday's sessionchartmill.com
Via Chartmill · April 21, 2026
Unusual volume stocks are being observed in Tuesday's session.chartmill.com
Via Chartmill · April 21, 2026
These stocks are moving in today's sessionchartmill.com
Via Chartmill · April 21, 2026
Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition
Company secures Commitment Letter from a leading financial institution of up to $22.5M to finance proposed acquisition of Dura Control Systems (DCS)
Via ACCESS Newswire · April 20, 2026
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo
Elite Ultra-Marathoner targets her second World Record in two months following historic
Via ACCESS Newswire · April 17, 2026
Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue
ESTERO, FL / ACCESS Newswire / April 16, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced it has entered into a Letter of Intent (LOI) to acquire Dura Driver Control Systems ("DCS"), a premier designer and manufacturer of automotive driver control systems that also apply to other industrial applications. Management of DCS will be bolstered by the addition of a team from Lakewood & Company with more than 100 years' collective experience within the automotive industry.
Via ACCESS Newswire · April 16, 2026
These stocks are moving in today's sessionchartmill.com
Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · April 15, 2026
Here are the top movers in Wednesday's session.chartmill.com
Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · April 15, 2026
Wednesday's session: gap up and gap down stockschartmill.com
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via Chartmill · April 15, 2026
These stocks are moving in today's pre-market sessionchartmill.com
Before the US market kicks off on Wednesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · April 15, 2026
Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion
Interwest to Drive Regional Growth for BUZZ BOMB™ Across Major Grocery and Convenience Channels
Via ACCESS Newswire · April 15, 2026
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.chartmill.com
Via Chartmill · March 25, 2026
Wednesday's session: top gainers and loserschartmill.com
Via Chartmill · March 25, 2026
Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion
Agreement Set to Expand BUZZ BOMB™ Distribution Across Natural, Specialty, and Mass Merchandiser Channels
Via ACCESS Newswire · March 19, 2026
Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director
ESTERO, FL / ACCESS Newswire / March 17, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, has appointed 25-year industry veteran John Choe as Western Sales Director. Choe joins the leadership team with a distinguished career of scaling consumer brands and leading high-performance teams across the retail and beverage sectors.
Via ACCESS Newswire · March 17, 2026
Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026
ESTERO, FL / ACCESS Newswire / March 12, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, announces its participation at The Health & Fitness (HFA) Show, scheduled for March 16-18 at the San Diego Convention Center.
Via ACCESS Newswire · March 12, 2026
Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack
Convenient Size at the Convenience Store
Via ACCESS Newswire · March 10, 2026
Stay updated with the stocks that are on the move in today's after-hours session.chartmill.com
Via Chartmill · March 6, 2026
Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief
Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety medication.
Via ACCESS Newswire · March 3, 2026
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship
BUZZ BOMB™ captures over 400,000 views and a spike in online revenue driven by strategic brand expansion and Ashley Paulson's historic record at the Jackpot Ultra Running Festival.
Via ACCESS Newswire · February 25, 2026
Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements
Company achieves minimum stockholders' equity rule; Nasdaq confirms matter is closed
Via ACCESS Newswire · February 20, 2026